Scientists find a new weakness in treatment-resistant prostate cancer
Scientists find a new weakness in treatment-resistant prostate cancer
Researchers at the University of Michigan identified a two‑drug strategy that may halt aggressive prostate cancers that escape hormone therapy by transdifferentiation. Combining BET bromodomain inhibitors with DNA‑methyltransferase (DNMT) inhibitors reversed many identity changes, sharply reduced tumor growth in preclinical models, and was well tolerated in mice, suggesting a promising approach for treatment‑resistant prostate cancer.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience